Twist Bioscience shareholders approve 100M share increase, equity plan amendment

Twist Bioscience Corp

Shareholders approved increase in authorized common stock by 100,000,000 shares (Proposal Five).
Amendment and restatement of 2018 Equity Incentive Plan approved; 3,700,000 new shares reserved (Proposal Four).
Directors Nelson Chan, Robert Ragusa, Melissa Starovasnik re-elected as Class I directors.
Non-binding advisory vote on NEO compensation passed with 49.6M votes for; 1.2M against.
Officer exculpation amendment approved (46.5M for, 4.3M against) effective upon filing Certificate of Amendment.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Twist Bioscience Corp: Amended the Amended and Restated Certificate of Incorporation to increase authorized common stock by 100,000,000 shares and provide for officer exculpation (effective 2025-02-10).

Change: charter amendment
Effective: 2025-02-10

Exact text from the filing

At the Annual Meeting, the Company’s stockholders approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (1) increase the number of shares of common stock of the Company authorized thereunder by an additional 100,000,000 shares and (2) provide for the exculpation of certain of the Company’s officers from liability in specific circumstances, as permitted by Delaware law (collectively, the “Charter Amendments”).

View on SEC.gov

Browse all governance changes →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001104659-25-011543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.